Log In
Print
BCIQ
Print
Print this Print this
 

Vaxira, Racotumomab

  Manage Alerts
Collapse Summary General Information
Company Recombio
DescriptionAnti-idiotype mAb that induces an immune response against N-glycolyl-containing gangliosides expressed in tumors
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentApproved
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsNon-small cell lung cancer (NSCLC)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today